Modern Management of BCG-Unresponsive NMIBC
With multiple FDA-approved therapies now available for BCG-unresponsive non–muscle invasive bladder cancer, this conversation explores how clinicians are finally moving beyond the era of limited...
NMIBC
Latest Posts
Bladder Cancer Diagnostics: Biomarkers, Cystoscopy, and Blue Light
Discover the latest advancements in bladder cancer diagnostics with leading experts Dr. Bogdana Schmidt, Dr....
Risk Calculators in Bladder Cancer Management
In this episode, Dr. Bogdana Schmidt, Dr. Piyush Agarwal, and Dr. Anne Schuckman explore the...
Managing Symptoms Post-Cystoscopy and TRBT
In the latest episode, Dr. Vignesh Packiam teams up with Dr. Sima Porten and Dr....
Evaluating Bladder Cancer Resection and Outcomes
In this episode, the discussion focuses on optimizing transurethral resection of bladder tumor (TURBT) and...
Intravesical Options Amidst BCG Shortage Challenges
In the face of a BCG shortage, how can we ensure the best care for...
Risk Stratification in Non-Muscle Invasive Bladder Cancer
"Now, I think it's very important to do risk stratification, because I think there is...